C.Q. Pharmaceutical Holding Adjusts Valuation Amid Strong Profit Growth and Market Dynamics

C.Q. Pharmaceutical Holding Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a nuanced view of the company's financial metrics and market position. The valuation metrics indicate a P/E ratio of 19, alongside a price-to-book value of 0.76, suggesting a fair valuation relative to its peers. The company has reported a notable pre-tax profit of CNY 124.11 million for the quarter ending September 2025, marking a significant growth of 161.57%. Additionally, the net profit for the first nine months stands at CNY 384.63 million, showcasing a solid performance despite a slight decline in profits over the past year. On the technical side, the stock's trends have shown a shift, with indicators reflecting a more bullish outlook on a monthly basis. The dividend yield remains attractive at 1.19%, further enhancing the stock's appeal. Overall, the adjustments in evaluation for C.Q. Pharmaceutical Holding Co., Ltd. highlight its evolving financial landscape and market dynamics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.